Artificial intelligence could be exactly what American healthcare needs

Cara Livernois | | Health Exec | Economics

If you believe the American healthcare system is in desperate need of a savior, researchers may have found a solution: the development of artificial intelligence With computers, smartphones and mobile applications becoming commonplace within health organizations, artificial intelligence is poised to be next on the list of integrated healthcare technology.

Innovations such as deep learning, natural language processing and artificial pancreases combating diabetes are just the tip of the iceberg for the implications of AI. Researchers believe AI is the solution to cutting costs while improving care quality within the next five to 10 years.

Read the full story below:

HOW ARTIFICIAL INTELLIGENCE WILL CURE AMERICA'S SICK HEALTH CARE SYSTEM

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.